Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening strategy aims to prevent uterine cancer in High-Risk women

NCT ID NCT05651282

Prevention Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a two-step screening process to find postmenopausal women at higher risk for endometrial cancer. Those identified as high-risk received a hormone challenge test and, if positive, standard care plus a lifestyle program. The goal was to see if this approach is practical and acceptable for preventing cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

96 people

The number who actually took part.

Started

Mar 2023

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals are postmenopausal (must be three (3) years past last menstrual period) * Individuals have an intact uterus (have not had a hysterectomy) Exclusion Criteria: * Individuals taking hormone therapy for menopause (including vaginal estrogen) * Individuals taking male hormones, * Individuals on anti-endocrine therapy (such as tamoxifen) * Individuals on aromatase inhibitor therapy * Individuals who have experienced abnormal uterine bleeding * Individuals who have an Intrauterine Device (IUD)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrium cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrium neoplasm endometrial cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrium cancer

Contacts and locations

Locations

  • VGH Research Pavilion

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.